絞り込み

18370

広告

Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention.

著者 Oyagüez I , Suárez C , López-Sendón JL , González-Juanatey JR , de Andrés-Nogales F , Suárez J , Polanco C , Soto J
Pharmacoecon Open.2019 Oct 31 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (73view , 0users)
Our objective was to assess the cost effectiveness of apixaban versus edoxaban in the prevention of stroke and systemic embolism (SE) in patients with atrial fibrillation (AF) in Spain.
PMID: 31673882 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード